As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.
8 Analysts have issued a Newron Pharmaceutical forecast:
8 Analysts have issued a Newron Pharmaceutical forecast:
Dec '24 |
+/-
%
|
||
Revenue | 48 48 |
467%
467%
|
|
Gross Profit | 48 48 |
488%
488%
|
|
EBITDA | 25 25 |
331%
331%
|
EBIT (Operating Income) EBIT | 25 25 |
325%
325%
|
Net Profit | 15 15 |
198%
198%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.
Head office | Italy |
CEO | Stefan Weber |
Employees | 22 |
Founded | 2002 |
Website | www.newron.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.